Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s Why

Posted by George Bondi on Sep 16th, 2026

Telix Pharmaceuticals Limited (NASDAQ:TLX – Get Free Report)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $12.83, but opened at $12.22. Telix Pharmaceuticals shares last traded at $11.7050, with a volume of 138,711 shares traded.

Analyst Upgrades and Downgrades

TLX has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $20.40.

Check Out Our Latest Research Report on TLX

Telix Pharmaceuticals Stock Performance

The stock’s 50 day moving average price is $11.25 and its 200-day moving average price is $10.24. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01.

Institutional Trading of Telix Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the period. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth $120,000. Lazard Asset Management LLC lifted its stake in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals during the second quarter valued at about $1,731,000.

About Telix Pharmaceuticals

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.